1. Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model
- Author
-
Oh Hyun Lee, Choongki Kim, Darae Kim, Chul Min Ahn, Donghoon Choi, Yangsoo Jang, Byeong Keuk Kim, Young Guk Ko, Seul Gee Lee, Se-Il Park, Jung Sun Kim, Myeong Ki Hong, Jung Jae Lee, Jaewon Oh, Seung Jun Lee, Yong Ho Lee, Sung Jin Hong, and Ok-Hee Jeon
- Subjects
medicine.medical_specialty ,Normal diet ,Sodium-glucose transporter-2 ,030204 cardiovascular system & hematology ,Nitric oxide ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,Sodium-glucose transporter 2 inhibitors ,Internal Medicine ,medicine ,030212 general & internal medicine ,Dapagliflozin ,Receptor ,business.industry ,Macrophages ,Balloon catheter ,medicine.disease ,Atherosclerosis ,Endocrinology ,Atheroma ,chemistry ,Sodium/Glucose Cotransporter 2 ,Tumor necrosis factor alpha ,Original Article ,Cardiology and Cardiovascular Medicine ,business - Abstract
BACKGROUND AND OBJECTIVES We sought to investigate an anti-atherosclerotic and anti-inflammatory effect of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in normoglycemic atherosclerotic rabbit model. METHODS Male New Zealand white rabbits (n=26) were fed with a 1% high-cholesterol diet for 7 weeks followed by normal diet for 2 weeks. After balloon catheter injury, the rabbits were administered with the Dapagliflozin (1mg/kg/day) or control-medium for 8 weeks (n=13 for each group). All lesions were assessed with angiography, optical coherence tomography (OCT), and histological assessment. RESULTS Atheroma burden (38.51±3.16% vs. 21.91±1.22%, p
- Published
- 2019